Ordering Recommendation

Evaluate the ability of a patient to produce antibody to a protein conjugated bacterial (H. influenza) vaccine to rule out antibody deficiency.

Mnemonic
HIBE IGG
Methodology

Quantitative Multiplex Bead Assay

Performed

Sun-Sat

Reported

1-2 days

New York DOH Approval Status
This test is New York DOH approved.
Specimen Required
Patient Preparation
Collect

Serum separator tube. "Pre" and 30-day "post" Haemophilus influenzae b vaccination specimens should be submitted together for testing. "Post" specimen should be drawn 30 days after immunization and must be received within 60 days of "pre" specimen.

Specimen Preparation

Separate serum from cells ASAP or within 2 hours of collection. Transfer 1 mL serum to an ARUP Standard Transport Tube. (Min: 0.15 mL) Mark specimens clearly as "Pre-Vaccine" or "Post-Vaccine".

Storage/Transport Temperature

Refrigerated.

Unacceptable Conditions

Plasma or other body fluids. Contaminated, hemolyzed or, severely lipemic specimens.

Remarks
Stability

After separation from cells: Ambient: 48 hours; Refrigerated: 2 weeks; Frozen: 1 year (avoid repeated freeze/thaw cycles)

Reference Interval

< 1.0 µg/mL = Antibody concentration not protective.
≥ 1.0 µg/mL = Antibody to H. influenzae b detected. Suggestive of protection.

Interpretive Data

Responder status is determined according to the ratio of post-vaccination concentration to pre-vaccination concentration of Haemophilus influenza b antibody, IgG as follows:
1.  If the post-vaccination concentration is less than 3.0 µg/mL, the patient is considered to be a nonresponder.
2.  If the post-vaccination concentration is greater than or equal to 3.0 µg/mL, a patient with a ratio of greater than or equal to 4 is a good responder, a ratio of 2-4 is a weak responder, and a ratio of less than 2 is considered a nonresponder.

Compliance Statement B: For laboratory developed tests not using a RUO kit, and for FDA approved, cleared or 510(k) exempt assays with alterations. This test was developed and its performance characteristics determined by ARUP Laboratories. The U. S. Food and Drug Administration has not approved or cleared this test; however, FDA clearance or approval is not currently required for clinical use. The results are not intended to be used as the sole means for clinical diagnosis or patient management decisions.

Note
Hotline History
N/A
CPT Codes

86317

Components
Component Test Code* Component Chart Name LOINC
0050542 Haemophilus influenzae b Antibody, IgG 11256-5
* Component test codes cannot be used to order tests. The information provided here is not sufficient for interface builds; for a complete test mix, please click the sidebar link to access the Interface Map.
Aliases
  • H. influenzae Antibody
  • Haemophilus influenzae b Vaccine Response
  • HIB (Haemophilus influenzae Type B) Vaccine Response
  • Vaccine Response
Haemophilus influenzae b Antibody, IgG